AU6600400A - Methods and means for inhibiting angiogenesis - Google Patents

Methods and means for inhibiting angiogenesis

Info

Publication number
AU6600400A
AU6600400A AU66004/00A AU6600400A AU6600400A AU 6600400 A AU6600400 A AU 6600400A AU 66004/00 A AU66004/00 A AU 66004/00A AU 6600400 A AU6600400 A AU 6600400A AU 6600400 A AU6600400 A AU 6600400A
Authority
AU
Australia
Prior art keywords
methods
inhibiting angiogenesis
angiogenesis
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66004/00A
Inventor
Robert Marius Walther De Waal
Wilhelmus Petrus Johannes Leenders
Nicolette Hermance Lubsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Introgene BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgene BV filed Critical Introgene BV
Publication of AU6600400A publication Critical patent/AU6600400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU66004/00A 1999-08-13 2000-08-14 Methods and means for inhibiting angiogenesis Abandoned AU6600400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99202641 1999-08-13
EP99202641 1999-08-13
PCT/NL2000/000570 WO2001012809A2 (en) 1999-08-13 2000-08-14 Heterodimeric vegf variants used for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
AU6600400A true AU6600400A (en) 2001-03-13

Family

ID=8240540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66004/00A Abandoned AU6600400A (en) 1999-08-13 2000-08-14 Methods and means for inhibiting angiogenesis

Country Status (2)

Country Link
AU (1) AU6600400A (en)
WO (1) WO2001012809A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338313A1 (en) * 2001-04-06 2002-10-21 Maxygen Holdings Ltd. Single chain dimeric polypeptides derived from the vegf family
EP2270042B1 (en) * 2002-09-12 2015-01-14 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Also Published As

Publication number Publication date
WO2001012809A2 (en) 2001-02-22
WO2001012809A3 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
AU2297001A (en) Telestrator system
AU1173201A (en) Skin-gripper
AU7989400A (en) Compounds and methods
AU3092999A (en) Digital-timeshare-exchange
AU3215500A (en) Compounds and methods
AU6197600A (en) Tactiovisual distance-to-exit exit-finding system
AU4784500A (en) Reduction apparatus
AU2929700A (en) Tong
AU2002211837A1 (en) Antiangiogenic polypeptides and methods for inhibiting angiogenesis
AU2678800A (en) Modified calycins
AU5869900A (en) Uv-imager system
AU5126400A (en) Integrated sample-processing system
AU4939800A (en) Subsurface apparatus
AU2804600A (en) Arylaminoalkylamides
AU2023701A (en) Sketcher
AU2699800A (en) Organoceramics
AU7566700A (en) Method and device for interlocking
AU4599500A (en) Safe
AU6600400A (en) Methods and means for inhibiting angiogenesis
AU1901801A (en) Glucofuranoses
AU4434600A (en) Reducer
AU2582200A (en) Windturbine
AU1915601A (en) Periotome
AU5552200A (en) Method
AU4616699A (en) Hydromagnetotherapy system

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase